Palupiprant is under clinical development by Adlai Nortye Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Palupiprant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
E-7046 (ER-886046) is under development for the treatment of rectal cancer, triple-negative breast cancer, esophageal cancer or esophagogastric junction cancer, squamous or non-squamous non-small cell lung cancer, urothelial carcinoma of the bladder, unspecified indication, microsatellite stable (MSS) colorectal cancer (CRC), cervical cancer and solid tumor. The drug candidate is a small molecule administered through oral route and formulated as a capsule. It acts by targeting EP4 receptor. It was also under development for the treatment of solid tumors such as pancreatic adenocarcinoma, renal clear cell carcinoma, squamous cell carcinoma of head and neck, non-small cell lung cancer, colorectal cancer, hepatocellular carcinoma, ovarian serous epithelial cancer, bladder transitional cancer, cervical cancer, triple-negative breast cancer and rheumatoid arthritis.
Adlai Nortye Biopharma overview
Adlai Nortye Biopharma (Adlai Nortye) is a biopharmaceutical company that discovers and develops drugs for oncology indications. The company is investigating AN2025, a trial-stage pan-PI3K inhibitor for the treatment of recurrent and metastatic head and neck squamous cell carcinoma; and AN0025, an EP4 antagonist designed against triple negative breast cancer, non-small-cell lung carcinoma, bladder, rectum and cervical cancer, and microsatellite stable colorectal cancer. It is also evaluating AN1004 to treat human epidermal growth factor receptor-2-negative metastatic breast cancer; AN4005 against advanced tumors; AN3025 and AN6025 for solid tumors. Adlai Nortye utilizes PAINT-2D and ANEAT-Id platform technologies to identify and develop immunotherapies and antibodies. The company operates research and development, clinical operation centers in China, and the US. Adlai Nortye is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of Palupiprant’s drug-specific PTSR and LoA scores, buy the report here.